• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Pract Lab Med . Diagnostic performance of an automated chemiluminescence immunoassay for SARS-CoV-2 IgG and IgM antibodies detection: A real life ex

tetano

Editor, Senior Moderator
Pract Lab Med


. 2021 May;25:e00227.
doi: 10.1016/j.plabm.2021.e00227. Epub 2021 Apr 19.
Diagnostic performance of an automated chemiluminescence immunoassay for SARS-CoV-2 IgG and IgM antibodies detection: A real life experience


Danilo Villalta[SUP] 1 [/SUP], Paola Martelli[SUP] 1 [/SUP], Anna Moratto[SUP] 1 [/SUP], Valeria Salgarolo[SUP] 1 [/SUP], Elita Ligato[SUP] 1 [/SUP], Mariaelisabetta Conte[SUP] 1 [/SUP], Roberto Giacomello[SUP] 1 [/SUP], Tommaso Pellis[SUP] 2 [/SUP], Rita De Rosa[SUP] 3 [/SUP], Sergio Venturini[SUP] 4 [/SUP], Massimo Crapis[SUP] 4 [/SUP]



Affiliations

Abstract

Background: Recently many serological assays for detection of antibodies to SARS-COV-2 virus were introduced on the market. Aim of this study was to assess the diagnostic performance of an automated CLIA for quantitative detection of anti-SARS-CoV-2 IgM and IgG antibodies.
Methods: A total of 354 sera, 89 from consecutive patients diagnosed with COVID-19 (43 mild, 32 severe and 13 critical) and 265 from asymptomatic and negative on rRT-PCR testing healthcare workers, were evaluated for IgM and IgG anti-SARS-CoV-2 antibodies with MAGLUMI immunoassay.
Results: The overall sensitivity and specificity were 86.5% (95%CI: 77.6-92.8) and 98.5% (95%CI:96.2-99.6), respectively. PPV, PPN, LR+, LR- and OR were 95.1 (95%CI: 87.8-98.6), 95.6 (95%CI: 92.4-97.7), 57.3 (95%CI: 21.6-152.1), 7.3 (95%CI: 4.31-12.4) and 418.6 (95%CI: 131.2-1335.2), respectively. The levels of SARS-CoV-2 IgM and IgG antibodies were 1.22 ?? ?1.2 AU/mL and 15.86 ?? ?24.83 AU/mL, 2.86 ?? ?2.4 AU/mL and 69.3 ?? ?55.5 AU/mL, 2.47 ?? ?1.33 AU/mL and 83.9 ?? ?83.9 AU/mL in mild, severe and critical COVID-19 groups, respectively. A significant difference in antibody levels between mild and severe/critical subjects has been shown.
Conclusions: The CLIA assay showed good diagnostic performance and a significant association between antibody levels and severity of the disease was found.

Keywords: Anti-SARS-CoV ?2 antibodies; Antibody levels; Coronavirus infectious disease 2019 (COVID-19); Diagnostic accuracy; Serological diagnosis.
 
Back
Top Bottom